citadel securities

Citadel Securities has initiated coverage on Dendreon (NASDAQ: DNDN) with a Neutral rating and $10 price target.

Citadel Securities has initiated coverage on Optimer Pharmaceuticals (NASDAQ: OPTR) with a Neutral rating and $10 price target.

Citadel Securities has initiated coverage on Human Genome Sciences (NASDAQ: HGSI) with an Add rating and $25 price target.

Citadel Securities has initiated coverage on Biogen Idec (NASDAQ: BIIB) with an Add rating and $130 price target.

Citadel Securities has initiated coverage on Forest Laboratories (NYSE: FRX) with a Neutral rating and $36 price target.

Citadel Securities has lowered its price target on Microchip Technology (NASDAQ: MCHP) from $30 to $28 in light of the company's expected results for CY2Q11. Says Citadel, in its report, “After the close, Microchip negatively pre-announced CY2Q11 results, indicating sales would decline 1.5% qoq...

Citadel Securities has an Add rating and a $46 price target on shares of CenturyLink, Inc. (NYSE: CTL). In a note to clients, Citadel Securities writes, "All three RLECs we cover have acknowledged that they will recognize significant benefits from 100% bonus depreciation this year. Based on...

Citadel Securities is upgrading shares of Frontier Communications Corp (NYSE: FTR) to Add from Neutral, and it is raising its price target to $9.50 from $8. In a note to clients, Citadel Securities writes, "We believe Frontier's integration of the Verizon properties is progressing smoothly, and...

Citadel Securities has upgraded Frontier Communications (NYSE: FTR) from Neutral to Add and has raised the price target from $8 to $9.50.

Citadel Securities has upgraded Hyatt Hotels Corporation (NYSE: H) from Neutral to Add and has raised the price target from $47 to $48.

According to Citadel Securities, Savient Pharmaceuticals (NASDAQ: SVNT) Neutral rating is reiterated. Citadel Securities said that the FDA's Arthritis Drugs Advisory Committee voted 11-1 against approval of Novartis' Ilaris for the treatment of gout flares in patients with an inadequate response...

Citadel commented on Texas Instruments (NYSE: TXN) in a report released yesterday. In the report, Citadel was negative in its assessment of the company. Citadel writes, "After the close, TI updated its 2Q11 outlook, lowering both the midpoint and low end of the prior range. Revenue guidance now...

Citadel Securities, which downgraded shares of United Therapeutics Corp. (NASDAQ: UTHR), is providing some color on the stock. “We are downgrading UTHR shares to Neutral from Add following the announcement of disappointing data from the FREEDOM-M study evaluating oral treprostinil monotherapy in...

Citadel Securities has downgraded United Therapeutics Corporation (NASDAQ: UTHR) from Add to Neutral and has lowered the price target from $70 to $60.

Leap Wireless (NASDAQ: LEAP) Edge Positive, $22 PT Metro PCS (NYSE: PCS) Neutral, $18 PT